The complexity of intestinal absorption and exsorption of digoxin in rats

International Journal of Pharmaceutics

Volumn 322, Issue 1-2, 2006, Pages 79-86

  Yao, Hsuan Ming ^a   Chiou, Win L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Brush border membrane vesicles (BBMV); Carrier mediated uptake; Digoxin; Organic anion transporting polypeptide (Oatp); P glycoprotein (P gp)

Indexed keywords

4,4' DIISOTHIOCYANATOSTILBENE 2,2' DISULFONIC ACID; BICARBONATE; BROMSULFOPHTHALEIN; DIGOXIN; ELACRIDAR; GLUTATHIONE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; ORGANIC ANION TRANSPORTER; PROTON; QUINIDINE; VERAPAMIL; VERLUKAST;

ANIMAL TISSUE; APPLE JUICE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG PENETRATION; DRUG UPTAKE; FOOD DRUG INTERACTION; INTESTINE ABSORPTION; INTESTINE BRUSH BORDER; INTESTINE MUCOSA PERMEABILITY; MALE; NONHUMAN; NONLINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; RAT;

4,4'-DIISOTHIOCYANOSTILBENE-2,2'-DISULFONIC ACID; ACRIDINES; ANIMALS; DIGOXIN; ILEUM; INTESTINAL ABSORPTION; JEJUNUM; MALE; MICROVILLI; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PROPIONATES; QUINIDINE; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; SULFOBROMOPHTHALEIN; TETRAHYDROISOQUINOLINES; VERAPAMIL;

EID: 33748299055     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.05.030     Document Type: Article

References (52)

1. Andersson K.E., Nyberg L., Dencker H., and Gothlin J. Absorption of digoxin in man after oral and intrasigmoid administration studied by portal vein catheterization. Eur. J. Clin. Pharmacol. 9 (1975) 39-47
2. 2+ channel antagonists inhibit the intestinal absorption of digoxin in the guinea-pig. Eur. J. Pharmacol. 230 (1993) 301-305
3. Caldwell J.H., Martin J.F., Dutta S., and Greenberger N.J. Intestinal absorption of digoxin-3H in the rat. Am. J. Physiol. 217 (1969) 1747-1751
4. Cavet M.E., West M., and Simmons N.L. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 118 (1996) 1389-1396
5. Chen Z.S., Kawabe T., Ono M., Aoki S., Sumizawa T., Furukawa T., Uchiumi T., Wada M., Kuwano M., and Akiyama S.I. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol. Pharmacol. 56 (1999) 1219-1228
6. Chiou W.L., and Kyle L.E. Differential thermal, solubility, and aging studies on various sources of digoxin and digitoxin powder: biopharmaceutical implications. J. Pharm. Sci. 68 (1979) 1224-1229
7. Chiou W.L., Ma C., Chung S.M., and Wu T.C. An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol. Clin. Pharmacol. Ther. 69 (2001) 79-81
8. Crowe A., and Lemaire M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm. Res. 15 (1998) 1666-1672
9. Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., and Kim R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27 (1999) 866-871
10. de Bruin M., Miyake K., Litman T., Robey R., and Bates S.E. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 146 (1999) 117-126
11. Dresser G.K., Bailey D.G., Leake B.F., Schwarz U.I., Dawson P.A., Freeman D.J., and Kim R.B. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71 (2002) 11-20
12. Evans W.E., Schentag J.J., and Jusko W.J. Applied pharmacokinetics: principles of therapeutic drug monitoring. Applied Therapeutics (1992), Vancouver, WA
13. Faelli A., Tosco M., Orsenigo M.N., and Esposito G. Effects of the stilbene derivatives SITS and DIDS on intestinal ATPase activities. Pharmacol. Res. Commun. 16 (1984) 339-350
14. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., and Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 265-269
15. Hagenbuch B., and Meier P.J. The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 1609 (2003) 1-18
16. Hager W.D., Mayersohn M., and Graves P.E. Digoxin bioavailability during quinidine administration. Clin. Pharmacol. Ther. 30 (1981) 594-599
17. Hall W.H., and Doherty J.E. Tritiated digoxin XVI. Gastric absorption. Am. J. Dig. Dis. 16 (1971) 903-908
18. Hinderling P.H., and Hartmann D. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther. Drug Monit. 13 (1991) 381-401
19. Huffman D.H. Clinical use of digitalis glycosides. Am. J. Hosp. Pharm. 33 (1976) 179-185
20. Hyafil F., Vergely C., Du Vignaud P., and Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53 (1993) 4595-4602
21. Johnson B.F., Lindenbaum J., Budnitz E., and Marwaha R. Variability of steady-state digoxin kinetics during administration of tablets or capsules. Clin. Pharmacol. Ther. 39 (1986) 306-312
22. Jounela A.J., Pentikainen P.J., and Sothmann A. Effect of particle size on the bioavailability of digoxin. Eur. J. Clin. Pharmacol. 8 (1975) 365-370
23. Kamath A.V., Yao M., Zhang Y., and Chong S. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J. Pharm. Sci. 94 (2004) 233-239
24. Kessler M., Acuto O., Storelli C., Murer H., Muller M., and Semenza G. A modified procedure for the rapid preparation of efficiently transporting vesicles from small intestinal brush border membranes. Their use in investigating some properties of d-glucose and choline transport systems. Biochim. Biophys. Acta 506 (1978) 136-154
25. Kobayashi D., Nozawa T., Imai K., Nezu J., Tsuji A., and Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther. 306 (2003) 703-708
26. Kramer W.G., and Reuning R.H. Use of area under the curve to estimate absolute bioavailability of digoxin. J. Pharm. Sci. 67 (1978) 141-142
27. Li L., Meier P.J., and Ballatori N. Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol. Pharmacol. 58 (2000) 335-340
28. Lin J.H., and Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42 (2003) 59-98
29. Lowes S., Cavet M.E., and Simmons N.L. Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. Eur. J. Pharmacol. 458 (2003) 49-56
30. Magnusson J.O., Bergdahl B., Bogentoft C., Jonsson U.E., and Tekenbergs L. Excretion of digoxin and its metabolites in urine after a single oral dose in healthy subjects. Biopharm. Drug Dispos. 3 (1982) 211-218
31. Marcus F.I. Current status of therapy with digoxin. Curr. Probl. Cardiol. 3 (1978) 1-41
32. Mayer U., Wagenaar E., Beijnen J.H., Smit J.W., Meijer D.K., van Asperen J., Borst P., and Schinkel A.H. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br. J. Pharmacol. 119 (1996) 1038-1044
33. Meister W., Benowitz N.L., and Benet L.Z. Unchanged absorption of digoxin tablets in patients with cardiac failure. Pharmacology 28 (1984) 90-94
34. Noe B., Hagenbuch B., Stieger B., and Meier P.J. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 10346-10350
35. Pavek P., Merino G., Wagenaar E., Bolscher E., Novotna M., Jonker J.W., and Schinkel A.H. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J. Pharmacol. Exp. Ther. 312 (2005) 144-152
36. Pedersen K.E., Christiansen B.D., Klitgaard N.A., and Nielsen-Kudsk F. Effect of quinidine on digoxin bioavailability. Eur. J. Clin. Pharmacol. 24 (1983) 41-47
37. Reichel C., Gao B., Van Montfoort J., Cattori V., Rahner C., Hagenbuch B., Stieger B., Kamisako T., and Meier P.J. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver. Gastroenterology 117 (1999) 688-695
38. Renes J., de Vries E.G., Nienhuis E.F., Jansen P.L., and Mèuller M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br. J. Pharmacol. 126 (1999) 681-688
39. Rodin S.M., and Johnson B.F. Pharmacokinetic interactions with digoxin. Clin. Pharmacokinet. 15 (1988) 227-244
40. Satlin L.M., Amin V., and Wolkoff A.W. Organic anion transporting polypeptide mediates organic anion/HCO3- exchange. J. Biol. Chem. 272 (1997) 26340-26345
41. Shaw T.R., Howard M.R., and Hamer J. Variation in the biological availability of digoxin. Lancet 2 (1972) 303-307
42. Spahn-Langguth H., Baktir G., Radschuweit A., Okyar A., Terhaag B., Ader P., Hanafy A., and Langguth P. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36 (1998) 16-24
43. Stephens R.H., O'Neill C.A., Warhurst A., Carlson G.L., Rowland M., and Warhurst G. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther. 296 (2001) 584-591
44. Stephens R.H., Tanianis-Hughes J., Higgs N.B., Humphrey M., and Warhurst G. Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine. J. Pharmacol. Exp. Ther. 303 (2002) 1095-1101
45. Su S.F., and Huang J.D. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab. Dispos. 24 (1996) 142-147
46. Takanaga H., Maeda H., Yabuuchi H., Tamai I., Higashida H., and Tsuji A. Nicotinic acid transport mediated by pH-dependent anion antiporter and proton cotransporter in rabbit intestinal brush-border membrane. J. Pharm. Pharmacol. 48 (1996) 1073-1077
47. Takara K., Ohnishi N., Horibe S., and Yokoyama T. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAS in small intestine. Drug Metab. Dispos. 31 (2003) 1235-1239
48. Tamai I., Saheki A., Saitoh R., Sai Y., Yamada I., and Tsuji A. Nonlinear intestinal absorption of 5-hydroxytryptamine receptor antagonist caused by absorptive and secretory transporters. J. Pharmacol. Exp. Ther. 283 (1997) 108-115
49. Ushigome F., Koyabu N., Satoh S., Tsukimori K., Nakano H., Nakamura T., Uchiumi T., Kuwano M., Ohtani H., and Sawada Y. Kinetic analysis of P-glycoprotein-mediated transport by using normal human placental brush-border membrane vesicles. Pharm. Res. 20 (2003) 38-44
50. Walters H.C., Craddock A.L., Fusegawa H., Willingham M.C., and Dawson P.A. Expression, transport properties, and chromosomal location of organic anion transporter subtype 3. Am. J. Physiol. Gastr. Liver Physiol. 279 (2000) G1188-G1200
51. Yacobi A., Stoll R.G., Chao G.C., Schwartz R.A., Weidler D.J., Ayers J.W., Sakmar E., Hallmark M., and Wagner J.G. The assessment of the intrasubject variability in digoxin absorption in man from two oral dosage forms. J. Clin. Pharmacol. 21 (1981) 301-310
52. Yuasa H., Amidon G.L., and Fleisher D. Peptide carrier-mediated transport in intestinal brush border membrane vesicles of rats and rabbits: cephradine uptake and inhibition. Pharm. Res. 10 (1993) 400-404